1. Home
  2. IPHA vs BRY Comparison

IPHA vs BRY Comparison

Compare IPHA & BRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • BRY
  • Stock Information
  • Founded
  • IPHA 1999
  • BRY 1909
  • Country
  • IPHA France
  • BRY United States
  • Employees
  • IPHA N/A
  • BRY N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • BRY Oil & Gas Production
  • Sector
  • IPHA Health Care
  • BRY Energy
  • Exchange
  • IPHA Nasdaq
  • BRY Nasdaq
  • Market Cap
  • IPHA 160.1M
  • BRY 186.1M
  • IPO Year
  • IPHA 2019
  • BRY N/A
  • Fundamental
  • Price
  • IPHA $1.97
  • BRY $2.40
  • Analyst Decision
  • IPHA Strong Buy
  • BRY Hold
  • Analyst Count
  • IPHA 1
  • BRY 1
  • Target Price
  • IPHA $11.50
  • BRY $5.00
  • AVG Volume (30 Days)
  • IPHA 28.5K
  • BRY 1.2M
  • Earning Date
  • IPHA 03-27-2025
  • BRY 05-08-2025
  • Dividend Yield
  • IPHA N/A
  • BRY 14.99%
  • EPS Growth
  • IPHA N/A
  • BRY N/A
  • EPS
  • IPHA N/A
  • BRY 0.25
  • Revenue
  • IPHA $20,831,349.00
  • BRY $783,841,000.00
  • Revenue This Year
  • IPHA $220.44
  • BRY N/A
  • Revenue Next Year
  • IPHA $81.85
  • BRY $2.60
  • P/E Ratio
  • IPHA N/A
  • BRY $9.60
  • Revenue Growth
  • IPHA N/A
  • BRY N/A
  • 52 Week Low
  • IPHA $1.29
  • BRY $2.11
  • 52 Week High
  • IPHA $3.51
  • BRY $8.88
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 53.30
  • BRY 35.10
  • Support Level
  • IPHA $1.81
  • BRY $2.20
  • Resistance Level
  • IPHA $2.00
  • BRY $2.37
  • Average True Range (ATR)
  • IPHA 0.14
  • BRY 0.22
  • MACD
  • IPHA 0.02
  • BRY -0.00
  • Stochastic Oscillator
  • IPHA 53.76
  • BRY 24.58

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About BRY Berry Corporation (bry)

Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.

Share on Social Networks: